Cargando…

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)

OBJECTIVE: To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (ESBL-E BSIs). DESIGN: Retrospective cohort study. SETTING: Tertiary-care, academic medica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, Catherine H., Venugopalan, Veena, Santevecchi, Barbara A., Voils, Stacy A., Ramphal, Reuben, Cherabuddi, Kartikeya, DeSear, Kathryn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615022/ https://www.ncbi.nlm.nih.gov/pubmed/36310806 http://dx.doi.org/10.1017/ash.2022.21

Ejemplares similares

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

2775. Clinical Outcomes and Treatment-Emergent Resistance of Piperacillin-tazobactam, Cefepime, Carbapenems and Fluoroquinolones for the Treatment of Bloodstream Infections due to AmpC β-Lactamase-Producing Enterobacterales
por: Jawanda, Jasanjeet, et al.
Publicado: (2023)

1101. Implementing a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center
por: Veena, Venugopalan, et al.
Publicado: (2021)

2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
por: Go, James, et al.
Publicado: (2018)

143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption
por: Boulos, John M, et al.
Publicado: (2020)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

A Comparison Between Cefepime and Piperacillin-Tazobactam in the Management of Septic Shock
por: Ross, Robert C, et al.
Publicado: (2021)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
por: Kim, Bo-Guen, et al.
Publicado: (2023)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

Impact of an Extended Infusion Β-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections
por: Klinker, Kenneth, et al.
Publicado: (2017)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

Progression of kidney injury with the combination of vancomycin and piperacillin-tazobactam or cefepime in sepsis-associated acute kidney injury
por: Whitenack, Kaylee, et al.
Publicado: (2022)

BIChromET: A Chromogenic Culture Medium for Detection of Piperacillin/Tazobactam and Cefepime Resistance in Pseudomonas aeruginosa
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

2576. Piperacillin-Tazobactam or Cefepime for Treatment of Third Generation Cephalosporin Resistant Pneumonia in Intensive Care Unit Patients
por: DeLaurentis, Clare, et al.
Publicado: (2023)

183. Impact of Revised Piperacillin/Tazobactam Clinical Breakpoints on Enterobacterales Isolates Identified in Blood Cultures
por: Moore, Nicholas M, et al.
Publicado: (2022)

Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients
por: Lu, Brian, et al.
Publicado: (2023)

2290. Carbapenem vs. Piperacillin–tazobactam Definitive Therapy for Patients with Bloodstream Infections Due to Ceftriaxone Not Susceptible Escherichia coli or Klebsiella species
por: MacVane, Shawn H, et al.
Publicado: (2019)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Incidence of Acute Kidney Injury Among Intensive Care Unit Patients Receiving Vancomycin in Combination with Cefepime or Piperacillin–Tazobactam
por: Rutter, W Cliff, et al.
Publicado: (2017)

50. Comparative Incidence of Acute Kidney Injury in Septic Patients Treated with Vancomycin in Combination with Piperacillin/Tazobactam vs. Cefepime
por: Deja, Erin, et al.
Publicado: (2020)

2893 B. Effect of Cefepime versus Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection: A Randomized Clinical Trial
por: Qian, Edward, et al.
Publicado: (2023)

LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales
por: Belley, Adam, et al.
Publicado: (2020)

1548. Characterizing Cefepime Neurotoxicity: Experience from a Tertiary Care Center Performing β-lactam Therapeutic Drug Monitoring
por: Nys, Cara, et al.
Publicado: (2019)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study
por: Herrmann, Lena, et al.
Publicado: (2021)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
por: Wang, Xueting, et al.
Publicado: (2023)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
por: Alsaleh, Nada A, et al.
Publicado: (2020)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
por: Baker, Thomas M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_28t295vqkluaqld8d0l9ev1l9d